Please fax all pages of completed form to your team at 866.531.1025.

To reach your team, call toll-free 866.839.2162.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Accredo® Specialty Pharmacy Prescription & Enrollment Form

Dupixent® (dupilumab)



Four simple steps to submit your referral.

digits of SSNApt # To receiving automated/artificial apply. Message frequency varies
digits of SSNApt # Zip to receiving automated/artificial apply. Message frequency varies
digits of SSN Apt # Zip to receiving automated/artificial apply. Message frequency varies
Apt # Apt # Zip to receiving automated/artificial apply. Message frequency varies
Zip
to receiving automated/artificial apply. Message frequency varies
to receiving automated/artificial apply. Message frequency varies
to receiving automated/artificial apply. Message frequency varies
to receiving automated/artificial apply. Message frequency varies
to receiving automated/artificial apply. Message frequency varies
to receiving automated/artificial apply. Message frequency varies
to receiving automated/artificial apply. Message frequency varies
to receiving automated/artificial apply. Message frequency varies
e prescription fullillinent.
nse #
Suite #
Zip
w dotted line:
Suite #
Zip
nse — — w c

Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name	Phone	
3 Clinical Information (cont	.)		
Lab results: History of positive skin OR RAST test	to a perennial aeroallergen		
Pre-treatment steroid dose mg	g Pre-treatment serum IgE level	IU per mL	Test date
Pre-treatment serum eosinophils	cells/mcL and/or sputum eosinophils		Oate
Patient wt kg Date wt obtained	ed		
MD Specialty (required): Allergist Pulmonologist	ENT Primary care Pediatrician [Dermatologist Other	
Prescription type: Naïve/new start Restart	Continued therapy		
Prior therapies: Please fax detailed medication history	y with dates of use as available. Required by	some plan authorization	n criteria.
Topical steroid(s) Oral antihistamines Topica	al PDE-4 inhibitor Oral steroids Oral ir	nmunosuppressants	
Topical calcineurin inhibitor Sinus surgery			
4. Prescribing Information			
—			

Medication	Strength / Formulation	Directions	Quantity/Refills
Dupixent® (dupilumab)	200mg/1.14mL pre-filled pen (2-pack) 200mg/1.14mL pre-filled syringe (2-pack) 300mg/2mL pre-filled pen (2-pack) 300mg/2mL pre-filled syringe (2-pack)	Starter Dose: If starter dose is NOT needed, DO NOT complete this section. Inject 400mg under the skin on Day 1 then 200mg every 2 weeks starting on day 15 and thereafter. Inject 600mg under the skin on Day 1 then 300mg every 2 weeks starting on day 15 and thereafter. Inject 600mg under the skin on Day 1 then 300mg every 4 weeks thereafter starting on day 29.	Starter dose: Qty 1 (2-pack) No refills
		Maintenance Dose: Inject 200mg under the skin every 2 weeks. Inject 300mg under the skin every 2 weeks. Inject 300mg under the skin every 4 weeks. No starter dose indicated or required: Inject 200mg under the skin every 2 weeks. Inject 200mg under the skin every 4 weeks. Inject 300mg under the skin once weekly. Inject 300mg under the skin every 2 weeks. Inject 300mg under the skin every 4 weeks.	Maintenance dose: Days supply Refills For orders without a starter dose: Days supply Refills Patient weight
Other			kg

If shipped to physician's office or infusion clinic, physician accepts on behalf of patient for administration in office or infusion clinic.

Prescriber's signature required (sign below)	(Physician attests this is his/her legal signature. NO STAMPS)
--	--



Date Dispense as written Date Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.



The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents. All rights in the product names, trade names or logos of all third-party products that appear in this form, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. © 2025 Evernorth Health Services. All rights reserved. AST-00003-111325 CRP1594902